SENS-AI
DCP Results Bearish

DIS-CHEM PHARMACIES LIMITED - INTERIM CONSOLIDATED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 AUGUST 2026 AND DIVIDEND DECLARATION

Dis-Chem Pharmacies Limited
Full analysis

What this filing means

Dis-Chem grew revenue 8.0% to R23.0 billion but earnings went the other way: headline earnings per share fell 12.8% to 64.3 cents and the interim dividend fell 12.9% to 25.62 cents, in line with the disclosed 40%-of-HEPS payout basis. The loyalty programme is winning customers — Better Rewards membership is up 27% to 8.2 million and front-shop volume grew 5.5% against a flat market — while expenses grew 12.1% and the X, bigly labs cost investment doubled. The filing reports these movements separately without attributing the earnings decline to any single driver.

Dis-Chem is selling more — revenue is up 8% — but it is making less profit on those sales. The loyalty programme is bringing in customers, while the company doubled cost investment in X, bigly labs to build its digital business. The dividend fell alongside the lower earnings because the payout is set at 40% of headline earnings. The filing reports the revenue growth, expense growth and investment separately, so the profit decline cannot be reduced to one cost line.

Bull case

  • Group revenue increased 8.0% to R23.0 billion despite constrained consumer spending.
  • Retail total income grew 11.1% while retail total income margin increased from 30.8% to 31.7%.
  • Dis-Chem front-shop volume grew 5.5%, versus 0.1% growth for the total market excluding Dis-Chem.
  • Group revenue continued to grow 7.9% in the seven weeks from 1 September to 19 October 2026.
  • Better Rewards active membership increased 27% to 8.2 million members.

Bear case

  • Basic earnings per share fell 13.3% to 64.1 cents from 73.9 cents despite revenue growth of 8.0%.
  • The declared interim dividend decreased 12.9% from the prior comparable period to 25.62181 cents per share.
  • Expenses increased 12.1% over the comparable period, reflecting a larger cost burden relative to reported revenue growth.
  • Inventory increased by R1 billion, or 13.2%, from February 2026 because stock was purchased in anticipation of the SEP increase.
  • The Group anticipates a more even distribution of earnings across 1H2027 and 2H2027 because of the higher invested cost base for X, bigly labs.

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

A clean earnings decline dressed in strong revenue growth. The loyalty programme is doing its job on the top line — membership, volume and market share are all up — while expenses grew 12.1% and HEPS fell 12.8%. The dividend fell 12.9% alongside HEPS under the disclosed 40%-of-HEPS payout basis. The reported result is negative even as revenue momentum remains intact, rather than a proven cost-overrun story. Management expects incremental investment in X, bigly labs to slow as the unit nears its established state, while the unwinding of deflationary base effects supports retail revenue growth; the bear case is the earnings and expense numbers in front of you. So what: the market still needs evidence that the earnings decline reverses before the growth story can support a stronger view.

Full-year results will show whether earnings recover as the X, bigly labs investment matures and retail revenue benefits from the unwinding of deflationary base effects.

Evidence from the filing

  • Group revenue increased 8.0% to R23.0 billion despite constrained consumer spending.

    “Group revenue R23.0 billion R21.3 billion 8.0%”

  • Retail total income grew 11.1% while retail total income margin increased from 30.8% to 31.7%.

    “Retail total income grew by 11.1% with retail total income margin increasing from 30.8% to 31.7% over the comparable period.”

  • Dis-Chem front-shop volume grew 5.5%, versus 0.1% growth for the total market excluding Dis-Chem.

    “Dis-Chem front shop volume growth of 5.5% against total market (excl. Dis-Chem) volume growth of 0.1% (as read by Nielsen”

  • Group revenue continued to grow 7.9% in the seven weeks from 1 September to 19 October 2026.

    “For the seven-week period 1 September to 19 October 2026, Group revenue grew by 7.9% over the prior comparable period.”

  • Better Rewards active membership increased 27% to 8.2 million members.

    “Active membership grew by 27% to 8.2 million members, with 760,000 reactivated members and 980,000 new members”

  • Basic earnings per share fell 13.3% to 64.1 cents from 73.9 cents despite revenue growth of 8.0%.

    “Earnings per share 64.1 cents 73.9 cents (13.3%)”

  • The declared interim dividend decreased 12.9% from the prior comparable period to 25.62181 cents per share.

    “2026 has been declared based on 40% of headline earnings. This is a decrease of 12.9% from the prior comparable period.”

  • Expenses increased 12.1% over the comparable period, reflecting a larger cost burden relative to reported revenue growth.

    “Expenses grew by 12.1% over the comparable period.”

  • Inventory increased by R1 billion, or 13.2%, from February 2026 because stock was purchased in anticipation of the SEP increase.

    “During the current period, the Group’s inventory increased by R1 billion or 13.2% from February 2026, as a result of inventory purchased”

  • The Group anticipates a more even distribution of earnings across 1H2027 and 2H2027 because of the higher invested cost base for X, bigly labs.

    “due to the higher invested cost base for X, bigly labs in 2H2026, contributing to an stronger full year earnings performance.”
Category
Results
Event posture
Bearish Continuation
Published
Oct 29, 2026

More on Dis-Chem Pharmacies Limited

Dis-Chem Pharmacies Limited (DCP) share price All Dis-Chem Pharmacies Limited SENS announcements

Related filings